Tag: Thomas Albrecht
CONSEQUENT trial 12-month data support drug-coated balloons for long lesions
Twelve-month results of the CONSEQUENT trial have shown lower late lumen loss, lower rates of 12-month target lesion revascularisation and longer walking distance increases...
